Organisation paid for research Program year 2024 Source: CMS Open Payments

Asthma Allergy Associates

Neither a doctor nor a teaching hospital

Research payments

$716,581

12 payments

Through program year 2024, Asthma Allergy Associates is reported as receiving $716,581 in research payments, across 12 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $427,094 5
2023 Research $193,988 4
2021 Research $5,070 1
2020 Research $4,782 1
2019 Research $85,647 1

Breakdown

Who paid Research payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $716,581 12 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy $195,650 2 payments
  2. A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy $190,519 3 payments
  3. A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (Lou064) at Multiple Dose Levels in Adult Participants With Peanut Allergy $144,047 2 payments
  4. A Two Treatment Epoch Randomized Placebo Controlled Multi Centered Parallel Group Study to Assess the Safety of Qaw039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma $90,429 2 payments
  5. A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $89,936 2 payments
  6. A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines $6,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record